Pfizer and BioNTech to supply the European Union with up to 1.8 billion additional doses of COMIRNATY

May 20, 2021  –  Pfizer Inc. and BioNTech SE announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY, the companies’ COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.

This new agreement is in addition to the 600 million doses that have already been committed to the EU through 2021.

The additional 900 million agreed doses are expected to be delivered on a monthly schedule beginning December 2021 and continuing into 2023.

As part of the agreement, the EC also has an option to increase the number of doses delivered by up to an additional 900 million, bringing the total number of potential doses delivered to the EC, inclusive of all agreements, to up to 2.4 billion.

All doses for the EC are planned to be manufactured in the European Union.

Pfizer and BioNTech are committed to the continued development of the vaccine, including evaluation of a potential booster dose, and an updated version of the vaccine to address potential variants.

Learn More